Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Change in Taxes (2019 - 2021)

Immunovant filings provide 3 years of Change in Taxes readings, the most recent being $512000.0 for Q1 2021.

  • Quarterly Change in Taxes rose 530.25% to $512000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $512000.0 through Mar 2021, up 3633.47% year-over-year, with the annual reading at $261000.0 for FY2025, 1473.68% up from the prior year.
  • Change in Taxes hit $512000.0 in Q1 2021 for Immunovant, up from $12000.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $512000.0 in Q1 2021 and bottomed at -$119000.0 in Q1 2020.
  • Average Change in Taxes over 3 years is $61313.8, with a median of $2500.0 recorded in 2019.
  • The largest annual shift saw Change in Taxes tumbled 1600.0% in 2020 before it soared 530.25% in 2021.
  • Immunovant's Change in Taxes stood at $95000.0 in 2019, then plummeted by 87.37% to $12000.0 in 2020, then skyrocketed by 4166.67% to $512000.0 in 2021.
  • Per Business Quant, the three most recent readings for IMVT's Change in Taxes are $512000.0 (Q1 2021), $12000.0 (Q3 2020), and -$12000.0 (Q2 2020).